Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALVO Alvotech	$8.87 +0.9%	$9.54	$7.35 ▼ $13.70	$2.65B	0.11	344,576 shs	217,383 shs
CRNX Crinetics Pharmaceuticals	$28.22 +1.4%	$30.74	$24.10 ▼ $62.53	$2.61B	0.33	812,219 shs	1.01 million shs
IMVT Immunovant	$16.09 +2.4%	$16.44	$12.72 ▼ $34.47	$2.69B	0.66	1.37 million shs	716,034 shs
KALV KalVista Pharmaceuticals	$13.31 +0.8%	$13.47	$7.30 ▼ $16.32	$659.89M	0.05	1.94 million shs	985,422 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALVO Alvotech	+0.91%	-9.58%	-3.48%	+10.74%	-23.14%
CRNX Crinetics Pharmaceuticals	+1.36%	-6.86%	-5.54%	-7.54%	-43.32%
IMVT Immunovant	+2.42%	-4.00%	-4.25%	+16.13%	-42.27%
KALV KalVista Pharmaceuticals	+0.76%	-1.92%	+11.85%	+6.62%	+1.06%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALVO Alvotech	3.884 of 5 stars	3.5	4.0	0.0	3.4	0.0	1.9
CRNX Crinetics Pharmaceuticals	3.3269 of 5 stars	3.4	0.0	3.7	2.2	2.5	0.0
IMVT Immunovant	1.6227 of 5 stars	3.4	0.0	0.0	3.1	1.7	0.0
KALV KalVista Pharmaceuticals	3.8535 of 5 stars	3.6	1.0	4.4	2.4	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALVO Alvotech	3.00	Buy	$14.00	57.84% Upside
CRNX Crinetics Pharmaceuticals	2.80	Moderate Buy	$69.50	146.28% Upside
IMVT Immunovant	2.82	Moderate Buy	$36.40	126.23% Upside
KALV KalVista Pharmaceuticals	3.11	Buy	$26.29	97.49% Upside

Current Analyst Ratings Breakdown

Latest KALV, CRNX, IMVT, and ALVO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/28/2025	IMVT Immunovant	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$17.00 ➝ $18.00
7/18/2025	ALVO Alvotech	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $14.00
7/10/2025	CRNX Crinetics Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$36.00
7/10/2025	IMVT Immunovant	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold	$18.00
7/8/2025	KALV KalVista Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$19.00 ➝ $27.00
7/8/2025	KALV KalVista Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$20.00 ➝ $27.00
7/7/2025	KALV KalVista Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$18.00 ➝ $20.00
6/27/2025	CRNX Crinetics Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$81.00

(Data available from 8/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALVO Alvotech	$491.98M	5.44	N/A	N/A	($1.37) per share	-6.47
CRNX Crinetics Pharmaceuticals	$1.04M	2,540.61	N/A	N/A	$14.29 per share	1.97
IMVT Immunovant	N/A	N/A	N/A	N/A	$4.16 per share	N/A
KALV KalVista Pharmaceuticals	N/A	N/A	N/A	N/A	$1.92 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALVO Alvotech	-$231.86M	$0.37	23.97	44.35	N/A	16.42%	-36.37%	12.70%	8/21/2025 (Estimated)
CRNX Crinetics Pharmaceuticals	-$298.41M	-$3.82	N/A	N/A	N/A	N/A	-30.95%	-28.12%	8/7/2025 (Estimated)
IMVT Immunovant	-$413.84M	-$2.74	N/A	N/A	N/A	N/A	-80.60%	-71.89%	8/5/2025 (Estimated)
KALV KalVista Pharmaceuticals	-$183.44M	-$3.69	N/A	N/A	N/A	N/A	-134.07%	-82.65%	9/4/2025 (Estimated)

Latest KALV, CRNX, IMVT, and ALVO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/21/2025	Q2 2025	ALVO Alvotech	-$0.06	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	CRNX Crinetics Pharmaceuticals	-$1.13	N/A	N/A	N/A	$0.52 million	N/A
8/5/2025	Q1 2026	IMVT Immunovant	-$0.69	N/A	N/A	N/A	N/A	N/A
7/10/2025	Q4 2025	KALV KalVista Pharmaceuticals	-$0.83	-$3.69	-$2.86	-$0.99	$4.20 million	N/A
5/29/2025	Q4 2025	IMVT Immunovant	-$0.72	-$0.64	+$0.08	-$0.64	N/A	$0.16 million
5/8/2025	Q1 2025	CRNX Crinetics Pharmaceuticals	-$0.99	-$1.04	-$0.05	-$1.04	$0.10 million	$0.36 million
5/7/2025	Q1 2025	ALVO Alvotech	-$0.17	$0.35	+$0.52	$0.35	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALVO Alvotech	N/A	N/A	N/A	N/A	N/A
CRNX Crinetics Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
IMVT Immunovant	N/A	N/A	N/A	N/A	N/A
KALV KalVista Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALVO Alvotech	N/A	1.73	1.19
CRNX Crinetics Pharmaceuticals	N/A	22.53	22.53
IMVT Immunovant	N/A	11.16	11.16
KALV KalVista Pharmaceuticals	N/A	5.35	5.35

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALVO Alvotech	N/A
CRNX Crinetics Pharmaceuticals	98.51%
IMVT Immunovant	47.08%
KALV KalVista Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
ALVO Alvotech	N/A
CRNX Crinetics Pharmaceuticals	6.00%
IMVT Immunovant	1.80%
KALV KalVista Pharmaceuticals	10.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALVO Alvotech	1,032	301.48 million	N/A	Not Optionable
CRNX Crinetics Pharmaceuticals	210	93.63 million	88.01 million	Optionable
IMVT Immunovant	120	171.07 million	167.99 million	Optionable
KALV KalVista Pharmaceuticals	100	49.95 million	44.71 million	Optionable

KALV, CRNX, IMVT, and ALVO Headlines

Recent News About These Companies

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 4 at 7:00 AM | businesswire.com

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives $26.29 Average Price Target from Brokerages

July 30, 2025 | americanbankingnews.com

EMA Backs First Oral Treatment for Hereditary Angioedema

July 29, 2025 | medscape.comM

KalVista Pharmaceuticals (KALV) Received Positive Opinion From the European Medicines Agency

July 29, 2025 | msn.com

KalVista Pharmaceuticals Ekterly Faces A Shrinking Market And Oral Competitor Threat (Downgrade)

July 27, 2025 | seekingalpha.com

KalVista Pharmaceuticals (NASDAQ:KALV) Stock Price Down 6.5% - Here's Why

July 26, 2025 | marketbeat.com

KALV - KalVista Pharmaceuticals Inc Key Metrics - Morningstar

July 25, 2025 | morningstar.comM

New medicines recommended for approval by EMA’s CHMP

July 25, 2025 | thepharmaletter.comT

KalVista Gets CHMP Backing for Ekterly in Hereditary Angioedema

July 25, 2025 | marketwatch.com

KalVista Pharmaceuticals (NASDAQ:KALV) Stock Price Crosses Above Fifty Day Moving Average - What's Next?

July 25, 2025 | marketbeat.com

KalVista Pharmaceuticals Receives Positive CHMP Opinion for Sebetralstat for the Treatment of Hereditary Angioedema Attacks

July 25, 2025 | businesswire.com

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Given Average Recommendation of "Buy" by Brokerages

July 25, 2025 | marketbeat.com

KalVista Pharmaceuticals receives UK MKRA marketing authorization for sebetralstat to treat hereditary angioedema attacks

July 18, 2025 | pharmabiz.comP

MHRA approves KalVista’ Ekterly to treat hereditary angioedema attacks

July 17, 2025 | pmlive.comP

Cantor Fitzgerald Issues Positive Forecast for KALV Earnings

July 16, 2025 | marketbeat.com

KalVista Gets U.K. Authorization for Hereditary Angioedema Treatment

July 15, 2025 | marketwatch.com

KalVista Pharmaceuticals Announces UK MHRA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema

July 15, 2025 | finance.yahoo.com

KalVista Pharmaceuticals Announces UK MHRA Approval of EKTERLYÂ® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema

July 15, 2025 | businesswire.com

MHRA approves Ekterly to treat HAE

July 15, 2025 | thepharmaletter.comT

The week in pharma: action, reaction and insight – week to July 11

July 13, 2025 | thepharmaletter.comT

Emerald Advisers LLC Has $10.37 Million Stake in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

July 13, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KALV, CRNX, IMVT, and ALVO Company Descriptions

Alvotech NASDAQ:ALVO

$8.87 +0.08 (+0.91%)

Closing price 08/4/2025 04:00 PM Eastern

Extended Trading

$8.93 +0.06 (+0.68%)

As of 04:54 AM Eastern

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.

Crinetics Pharmaceuticals NASDAQ:CRNX

$28.22 +0.38 (+1.36%)

Closing price 08/4/2025 04:00 PM Eastern

Extended Trading

$70.00 +41.78 (+148.05%)

As of 04:00 AM Eastern

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Immunovant NASDAQ:IMVT

$16.09 +0.38 (+2.42%)

Closing price 08/4/2025 04:00 PM Eastern

Extended Trading

$16.33 +0.24 (+1.49%)

As of 05:15 AM Eastern

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

KalVista Pharmaceuticals NASDAQ:KALV

$13.31 +0.10 (+0.76%)

Closing price 08/4/2025 04:00 PM Eastern

Extended Trading

$13.20 -0.11 (-0.83%)

As of 04:53 AM Eastern

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time